The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Glofit-GemOx vs R-GemOx for R/R DLBCL: Results from the STARGLO trial
|
Results from the phase III STARGLO trial (NCT04408638) of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) vs rituximab plus gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) were presented at the European Hematology Association (EHA) 2024 Hybrid Congress by Abramson.1 |
| Key learnings: |
|
The primary endpoint of overall survival (OS) was met. |
|
After a median follow-up of 20.7 months, median OS was 25.5 months vs 12.9 months in the Glofit-GemOx and R-GemOx arms, respectively (hazard ratio [HR], 0.62; p = 0.006). |
|
Glofit-GemOx was associated with improved progression-free survival (PFS) and a higher complete response (CR) rate vs R-GemOx: median PFS was 13.8 months vs 3.6 months (HR, 0.40; p < 0.000001) and the CR rates were 58.5% vs 25.3% (p < 0.0001), respectively. |
|
The safety profile of Glofit-GemOx was consistent with that of the individual agents. |
|
Glofitamab is the first CD20xCD3 bispecific antibody to demonstrate a survival benefit in DLBCL in a randomized phase III trial. |
| The efficacy data from the phase III STARGLO trial and the tolerable safety profile of Glofit-GemOx supports the use of Glofit-GemOx in the treatment of patients with R/R DLBCL. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
